Johnson & Johnson (NYSE:JNJ) had its price target lifted by Jefferies Group LLC from $157.00 to $160.00 in a note issued to investors on Monday. The firm presently has a “buy” rating on the stock. Jefferies Group LLC’s price objective points to a potential upside of 12.36% from the stock’s previous close. Jefferies Group also issued estimates for Johnson & Johnson’s FY2017 earnings at $7.27 EPS, FY2018 earnings at $8.18 EPS, FY2019 earnings at $8.96 EPS, FY2020 earnings at $9.69 EPS and FY2021 earnings at $10.58 EPS.

A number of other analysts have also recently commented on JNJ. Barclays PLC upped their price target on Johnson & Johnson from $140.00 to $148.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Cowen and Company restated an “outperform” rating and issued a $155.00 price target (up previously from $147.00) on shares of Johnson & Johnson in a research report on Wednesday. Morgan Stanley restated a “hold” rating and issued a $145.00 price target (up previously from $140.00) on shares of Johnson & Johnson in a research report on Wednesday. Argus upped their price target on Johnson & Johnson from $145.00 to $165.00 and gave the stock a “positive” rating in a research report on Wednesday. Finally, Wells Fargo & Company restated an “outperform” rating and issued a $155.00 price target (up previously from $149.00) on shares of Johnson & Johnson in a research report on Wednesday. Five analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have given a buy rating to the company. Johnson & Johnson presently has a consensus rating of “Hold” and a consensus target price of $141.66.

Shares of Johnson & Johnson (JNJ) traded up 0.25% during midday trading on Monday, reaching $142.40. The company had a trading volume of 5,634,523 shares. The company’s 50-day moving average is $133.77 and its 200-day moving average is $130.75. The stock has a market capitalization of $382.20 billion, a PE ratio of 24.77 and a beta of 0.78. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $143.62.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. The company had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a return on equity of 27.68% and a net margin of 21.28%. Johnson & Johnson’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.68 earnings per share. On average, equities research analysts forecast that Johnson & Johnson will post $7.27 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/22/johnson-johnson-jnj-given-new-160-00-price-target-at-jefferies-group-llc.html.

In other Johnson & Johnson news, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the transaction, the vice president now directly owns 230,342 shares in the company, valued at approximately $30,667,733.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.19% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Harding Loevner LP purchased a new position in shares of Johnson & Johnson in the 2nd quarter valued at $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its holdings in shares of Johnson & Johnson by 29.9% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares during the period. Lenox Wealth Advisors Inc. increased its holdings in shares of Johnson & Johnson by 0.6% in the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after acquiring an additional 5 shares during the period. Mountain Capital Investment Advisors Inc purchased a new position in shares of Johnson & Johnson in the 2nd quarter valued at $124,000. Finally, Harel Insurance Investments & Financial Services Ltd. increased its holdings in shares of Johnson & Johnson by 241.0% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock valued at $149,000 after acquiring an additional 841 shares during the period. Institutional investors own 65.90% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.